Wex Pharmaceuticals Inc. Announces Successful Reexamination of Key Patent Covering Uses of Tectin

VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 29, 2008) - WEX Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) announced today that the U.S. Patent and Trademark Office has issued a Reexamination Certificate for United States Patent No. 6,407,088, titled "Method of Analgesia". This patent relates to the use of tetrodotoxin (TTX) for producing analgesia in humans. The successful reexamination strengthens the intellectual property rights for Tectin, the Company's lead product candidate.

Back to news